Goodwin’s Life Sciences team advised Gemini Therapeutics on the completion of its $42.5 million Series A financing round to advance multiple programs into the clinic. Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A, and also invested in seed financing in 2016. Gemini is developing first-in-class therapeutics built on the strong foundation of human genetics research in age-related macular degeneration (AMD), the leading cause of irreversible blindness in the U.S. and EU.
Gemini Therapeutics is a precision medicine company focused on genetically defined dry AMD and associated rare genetic diseases.
The Goodwin team was led by partners Mitchell Bloom and included counsel Kathleen Kean.